PFS Stock Recent News

Provident Financial Services, Inc. (NYSE:PFS ) Q4 2024 Results Conference Call January 29, 2025 10:00 AM ET Company Participants Adriano Duarte - Head & Investor Relations Officer Tony Labozzetta - President and Chief Executive Officer Tom Lyons - Senior Executive Vice President and Chief Financial Officer Conference Call Participants Mark Fitzgibbon - Piper Sandler Billy Young - RBC Capital Markets Tim Switzer - KBW Feddie Strickland - Hovde Group Manuel Navas - D.A. Davidson Operator Good morning, and welcome everyone to the Provident Financial Services, Inc. Fourth Quarter Earnings Conference Call.

The headline numbers for Provident Financial (PFS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Provident Financial (PFS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.36 per share a year ago.

ISELIN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) reported net income of $48.5 million, or $0.37 per basic and diluted share for the three months ended December 31, 2024, compared to $46.4 million, or $0.36 per basic and diluted share, for the three months ended September 30, 2024 and $27.3 million, or $0.36 per basic and diluted share, for the three months ended December 31, 2023. For the year ended December 31, 2024, net income totaled $115.5 million, or $1.05 per basic and diluted share, compared to $128.4 million, or $1.72 per basic and $1.71 per diluted share, for the year ended December 31, 2023.

HONG KONG , Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK)  (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently developed PD-1/CTLA-4 bispecific antibody, 开坦尼® (cadonilimab), in combination with or without platinum-based chemotherapy and bevacizumab, compared to placebo with platinum-based chemotherapy and bevacizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Funding is provided through the bank's Community Partnership Program Funding is provided through the bank's Community Partnership Program

VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ - New Pacific Metals Corp. (TSX: NUAG) (NYSE-A: NEWP) ("New Pacific" or the "Company") is pleased to report the filing of an independent Pre-Feasibility Study ("PFS") technical report for its Silver Sand project (the "Project") located in Potosi, Bolivia with an effective date of June 19, 2024 (the "PFS Technical Report"). The PFS Technical Report was prepared in accordance with the Canadian Securities Administrators' National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101").

ISELIN, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Provident Bank ,  a leading New Jersey-based financial institution, is pleased to welcome Leonardo Ramos as Vice President, Community Reinvestment Act (CRA) Officer.

Provident Financial Services, Inc. (NYSE:PFS ) Q2 2024 Results Conference Call July 26, 2024 10:00 AM ET Company Participants Adriano Duarte - Head of Investor Relations Tony Labozzetta - President and CEO Tom Lyons - Senior EVP, CFO Conference Call Participants Mark Fitzgibbon - Piper Sandler Tim Switzer - KBW Billy Young - RBC Capital Markets Operator [Call Started Abruptly] I would now like to turn the call over to Adriano Duarte, Head of Investor Relations. Adriano. Please go ahead.

Although the revenue and EPS for Provident Financial (PFS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.